StageZero Life Sciences Reports Q1 2024 Financial Performance and Operational Highlights

StageZero Life Sciences, a healthcare company specializing in mRNA-based cancer diagnostics and treatments, announced its financial results for the first quarter of 2024. The company recorded revenue of $0.523 million from its cancer testing and treatment services. This marks a decrease from the $0.778 million reported in the same period of 2023. However, the company also reduced its net loss to $0.386 million from $1.812 million year-over-year.

StageZero emphasized advancements in its "Aristotle" screening program, a multi-cancer diagnostic test, and revealed continuing expansion efforts in both the U.S. and Canada through various partnerships. The company also noted operational improvements at its Richmond laboratory and detailed new business developments aiming at expanding its European market footprint.

Looking forward, StageZero outlined several catalysts for 2024, including new partnerships, expansion into the employer market in the U.S., and the launch of their updated COC Protocol in Europe. The company’s financial statements and further management discussions are available on www.sedar.com.